Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: Potential models

Gynecologic Oncology

Volumn 96, Issue 1, 2005, Pages 48-55

  Lee, Cheng Han ^a   Xue, Hui ^b   Sutcliffe, Margaret ^b   Gout, Peter W ^b   Huntsman, David G ^a,b   Miller, Dianne M ^b   Gilks, C Blake ^a   Wang, Y Z ^b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

In vivo; Ovarian tumor tissue; Renal capsule

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; EOSIN; HEMATOXYLIN; INHIBIN; KERATIN; KI 67 ANTIGEN;

ADENOCARCINOMA; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER TISSUE; CONTROLLED STUDY; CYSTADENOMA; EPITHELIUM TUMOR; FEMALE; GRANULOSA CELL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KIDNEY CAPSULE; MOUSE; NONHUMAN; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; SCID MOUSE; SURGICAL TECHNIQUE; TIME; TUMOR CLASSIFICATION; XENOGRAFT;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOPHENOTYPING; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; SUBRENAL CAPSULE ASSAY; TRANSPLANTATION, HETEROLOGOUS;

EID: 10044265362     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.09.025     Document Type: Article

References (20)

1. L.L. McCluskey, and L. Dubeau Biology of ovarian cancer Curr. Opin. Oncol. 9 5 1997 465 470
2. R.N. Buick, R. Pullano, and J.M. Trent Comparative properties of five human ovarian adenocarcinoma cell lines Cancer Res. 45 8 1985 3668 3676
3. E. Boven, M.M. Nauta, H.M. Schluper, C.A. Erkelens, and H.M. Pinedo Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts Cancer Chemother. Pharmacol. 18 2 1986 124 128
4. C.F. Verschraegen, W. Hu, Y. Du, J. Mendoza, J. Early, and M. Deavers Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers Clin. Cancer Res. 9 2 2003 845 852
5. U. Schumacher, E. Adam, H.P. Horny, and J. Dietl Transplantation of a human ovarian cystadenocarcinoma into severe combined immunodeficient (SCID) mice-formation of metastases without significant alteration of the tumour cell phenotype Int. J. Exp. Pathol. 77 5 1996 219 227
6. J.C. Elkas, R.L. Baldwin, M. Pegram, Y. Tseng, D. Slamon, and B.Y. Karlan A human ovarian carcinoma murine xenograft model useful for preclinical trials Gynecol. Oncol. 87 2 2002 200 206
7. K. Kiguchi, T. Kubota, D. Aoki, Y. Udagawa, S. Yamanouchi, and M. Saga A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer Clin. Exp. Metastasis 16 8 1998 751 756
8. Y. Aubard Ovarian tissue xenografting Eur. J. Obstet. Gynecol. Reprod. Biol. 108 1 2003 14 18
9. A.E. Bogden, P.M. Haskell, D.J. LePage, D.E. Kelton, W.R. Cobb, and H.J. Esber Growth of human tumor xenografts implanted under the renal capsule of normal immunocompetent mice Exp. Cell Biol. 47 4 1979 281 293
10. A.E. Bogden, W.R. Cobb, D.J. Lepage, P.M. Haskell, T.A. Gulkin, and A. Ward Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse: six-day subrenal capsule assay Cancer 48 1 1981 10 20
11. T.W. Griffin, A.E. Bogden, S.D. Reich, D. Antonelli, R.E. Hunter, and A. Ward Initial clinical trials of the subrenal capsule assay as a predictor of tumor response to chemotherapy Cancer 52 12 1983 2185 2192
12. J.A. Stratton, P.R. Kucera, M.A. Rettenmaier, K. Dobashi, J.P. Micha, and P.S. Braly Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatin Gynecol. Oncol. 25 3 1986 302 310
13. W. Kleine In vivo chemosensitivity test models for gynecologic malignancies: methodology and results O.R. Kochli B.U. Sevin U. Haller Chemosensitivity testing in gynecologic malignancies and breast cancer 1994 Karger Basel 76 81
14. Y.Z. Wang, D. Sudilovsky, M. Cao, W. Chen, L. Goetz, and H. Xue Establishing efficient xenograft models of low-grade human prostate cancer Eur. Urol., Suppl. 2 6 2003 30
15. Y.Z. Wang, D. Sudilovsky, B. Zhang, P.C. Haughney, M.A. Rosen, and D.S. Wu A human prostatic epithelial model of hormonal carcinogenesis Cancer Res. 61 16 2001 6064 6072
16. C.L. Liu, W. Prapong, Y. Natkunam, A. Alizadeh, K. Montgomery, and C.B. Gilks Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays Am. J. Pathol. 161 5 2002 1557 1565
17. S.M. Pupa, S. Menard, S. Forti, and E. Tagliabue New insights into the role of extracellular matrix during tumor onset and progression J. Cell. Physiol. 192 3 2002 259 567
18. P.A. Kenny, and M.J. Bissell Tumor reversion: correction of malignant behavior by microenvironmental cues Int. J. Cancer 107 5 2003 688 695
19. G. Singer, R. Oldt III, Y. Cohen, B.G. Wang, D. Sidransky, and R.J. Kurman Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J. Natl. Cancer Inst. 95 6 2003 484 486
20. G. Singer, M. Shih Ie, A. Truskinovsky, and H. Umudum Mutational analysis of K-ras segregated ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor) Int. J. Gynecol. Pathol. 22 2003 37 41